Mari Ariyasu
- Molecular Medicine top 0.2%
- Pharmacology top 1%
- Applied Microbiology and Biotechnology top 0.2%
- Epidemiology top 10%
- Endocrinology top 2%
- Co-authors
- Tsutae Den NagataRoger EcholsSimon PortsmouthYuko MatsunagaRichard G. WunderinkJuan Camilo Arjona FerreiraMitsuaki MachidaDavid van Veenhuyzen
- Topics
- Antibiotics Pharmacokinetics and Efficacy (17 papers)Antibiotic Resistance in Bacteria (15 papers)SARS-CoV-2 and COVID-19 Research (7 papers)
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Mari Ariyasu
25 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 79
- Molecular Medicine 1.2k
- Pharmacology 873
- Applied Microbiology and Biotechnology 561
- Epidemiology 428
- Endocrinology 183
Countries citing papers authored by Mari Ariyasu
This map shows the geographic impact of Mari Ariyasu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mari Ariyasu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mari Ariyasu more than expected).
Fields of papers citing papers by Mari Ariyasu
This network shows the impact of papers produced by Mari Ariyasu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mari Ariyasu. The network helps show where Mari Ariyasu may publish in the future.
Co-authorship network of co-authors of Mari Ariyasu
This figure shows the co-authorship network connecting the top 25 collaborators of Mari Ariyasu. A scholar is included among the top collaborators of Mari Ariyasu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mari Ariyasu. Mari Ariyasu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | 4 | |
| 4 | 2 | |
| 5 | 1 | |
| 6 | 12 | |
| 7 | 11 | |
| 8 | 2 | |
| 9 | 2 | |
| 10 | Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trialbreakdown → | 319 |
| 11 | 5 | |
| 12 | 3 | |
| 13 | Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialbreakdown → | 540 |
| 14 | 1 | |
| 15 | 27 | |
| 16 | 25 | |
| 17 | 13 | |
| 18 | Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trialbreakdown → | 305 |
| 19 | 24 | |
| 20 | 139 |
About Mari Ariyasu
Mari Ariyasu is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine and Pharmacology, having authored 26 papers that have together received 1.5k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (17 papers), Antibiotic Resistance in Bacteria (15 papers) and SARS-CoV-2 and COVID-19 Research (7 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (561 citations), Molecular Medicine (1.2k citations) and Pharmacology (873 citations). Mari Ariyasu has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Tsutae Den Nagata, Roger Echols, Simon Portsmouth, Yuko Matsunaga, Richard G. Wunderink, Juan Camilo Arjona Ferreira, Mitsuaki Machida, David van Veenhuyzen, Matteo Bassetti and Kiichiro Toyoizumi. Their work appears in journals such as Clinical Infectious Diseases, Scientific Reports and The Lancet Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.